rel-2-((1R,2R)-2-(5,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl)-3-methylimidazo[2,1-f][1,6]naphthyridine
97%
- Product Code: 230517
CAS:
1516895-53-6
Molecular Weight: | 369.42 g./mol | Molecular Formula: | C₂₁H₁₉N₇ |
---|---|---|---|
EC Number: | MDL Number: | MFCD30345535 | |
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | 2-8°C, dry seal |
Product Description:
Used in pharmaceutical research as a potent inhibitor targeting specific kinases involved in inflammatory and oncogenic pathways. Shows promise in preclinical studies for treating certain solid tumors due to its ability to selectively modulate signaling proteins involved in cell proliferation and survival. Also investigated for its metabolic stability and bioavailability in oral formulations, making it a candidate for further development in targeted cancer therapies.
Sizes / Availability / Pricing:
Size | Availability | Price | Quantity |
---|---|---|---|
100mg | 10-20 days | ฿2,330.00 |
+
-
|
250mg | 10-20 days | ฿4,660.00 |
+
-
|
rel-2-((1R,2R)-2-(5,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl)-3-methylimidazo[2,1-f][1,6]naphthyridine
Used in pharmaceutical research as a potent inhibitor targeting specific kinases involved in inflammatory and oncogenic pathways. Shows promise in preclinical studies for treating certain solid tumors due to its ability to selectively modulate signaling proteins involved in cell proliferation and survival. Also investigated for its metabolic stability and bioavailability in oral formulations, making it a candidate for further development in targeted cancer therapies.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :